登出

Short Interest in Celyad Oncology SA (NASDAQ:CYAD) Grows By 374.5%

对Celyad Oncology SA（纳斯达克股票代码：CYAD）的空头兴趣增长了374.5％

Financial News Live · 2022/08/25 21:41

Celyad Oncology SA (NASDAQ:CYAD – Get Rating) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totalling 177,000 shares, a growth of 374.5% from the July 31st total of 37,300 shares. Based on an average trading volume of 136,100 shares, the days-to-cover ratio is currently 1.3 days.

Celyad Oncology Stock Performance

Shares of NASDAQ CYAD traded down $0.05 during mid-day trading on Thursday, reaching $1.95. 10,138 shares of the company traded hands, compared to its average volume of 66,226. Celyad Oncology has a fifty-two week low of $1.51 and a fifty-two week high of $5.32. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.71 and a quick ratio of 2.58. The stock has a fifty day simple moving average of $1.87 and a 200-day simple moving average of $2.13.

Get Celyad Oncology alerts:

Celyad Oncology Company Profile

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Celyad肿瘤学股票表现

周四午盘，纳斯达克赛德的股价下跌0.05美元，至1.95美元。该公司有10,138股易手，而其平均成交量为66,226股。Celyad Oncology的股价为52周低点1.51美元，52周高点为5.32美元。该公司的债务权益比为0.05，流动比率为1.71，速动比率为2.58。该股的50日简单移动均线为1.87美元，200日简单移动均线为2.13美元。

到达塞利亚德肿瘤学警报：

Celyad肿瘤学公司简介

(获取评级)

Celyad Oncology SA是一家临床阶段的生物制药公司，专注于发现和开发用于癌症治疗的嵌合抗原受体T(CAR-T)细胞疗法。它的主要候选产品包括用于治疗转移性结直肠癌的同种异体CAR-T候选药物Cyad-101，处于1b期临床试验的转移性结直肠癌；基于短发夹状RNA(ShRNA)的同种异体CAR-T候选药物，正处于治疗复发/难治性多发性骨髓瘤的第一阶段临床试验；以及正在进行第一阶段临床试验的自体CAR-T候选药物Cyad-02，用于治疗复发或难治性急性髓系白血病和骨髓增生异常综合征。

进一步阅读

免费获取StockNews.com关于Celyad肿瘤学的研究报告(CyAD)
威廉姆斯-索诺马的高端消费者仍在消费
雪花股票因业绩强劲而飙升
股价下跌40%的Shockwave Stunts：这是买入吗？
NVIDIA：分流芯片市场的首选？
宾夕法尼亚娱乐公司股票重置，准备反弹

接受Celyad肿瘤学日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Celyad Oncology和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Short Interest in Celyad Oncology SA (NASDAQ:CYAD) Grows By 374.5%

Short Interest in Celyad Oncology SA (NASDAQ:CYAD) Grows By 374.5%

Celyad Oncology Stock Performance

Celyad Oncology Company Profile

Further Reading

Celyad肿瘤学股票表现

Celyad肿瘤学公司简介

进一步阅读

风险及免责提示

声明